 |
31 Diseases |  |
34 Trials |
|
34 Trials |  |
1690 News |  |
| 12345678910111213...1819» |
- | linagliptin / Generic mfg.
Preclinical, Journal, IO biomarker: Linagliptin Mitigates DMH-Induced Colorectal Cancer in Rats: Crosstalk Between NFAT and IL-6/JAK2/STAT3/NF-?B Signaling Hubs. (Pubmed Central) - Mar 12, 2025
The histopathological analysis revealed that linagliptin has inhibitory potential against the DMH induced dysplastic aberrant crypt foci (ACF) and adenocarcinoma. Linagliptin ameliorated CRC by modulating NFAT-mediated IL-6 with JAK2/STAT3/NF-?B signaling cascades.
- | linagliptin / Generic mfg., Marizev (omarigliptin) / Merck (MSD)
Journal: Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake. (Pubmed Central) - Mar 6, 2025
Linagliptin ameliorated CRC by modulating NFAT-mediated IL-6 with JAK2/STAT3/NF-?B signaling cascades. Convergent findings across humans, mice, and rats indicate that GLP-1RAs but not DPP-4Is reduce alcohol consumption and may be efficacious in treating AUD.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: Zirconium nanoparticles decorated chitosan@hematoxylin/pencil graphite as a novel voltammetric sensor for monitoring of linagliptin/dapagliflozin co-therapy. (Pubmed Central) - Mar 6, 2025
The proposed SWV method represents the prototype of electrochemical techniques for the concurrent quantitation of LNG and DPZ in plasma samples. This method would have great value to support the pharmacokinetic studies, therapeutic drug monitoring, and refining the safety profile of fixed-dose combined therapy with LNG/DPZ.
- ||| Journal, Adverse events: Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis. (Pubmed Central) - Mar 5, 2025
DPP-4 inhibitors are potentially linked to biliary disorders, warranting vigilance. While the overall association for GLP-1 RAs was not significant, specific drugs like semaglutide, liraglutide, and sitagliptin showed concerning signals, suggesting a need for heightened awareness among clinicians regarding the risk of biliary AEs.
- | Nesina (alogliptin) / Takeda
Journal: Association of statins, gliptins, and antipsychotics with bullous pemphigoid: A case-control study in the Cretan population. (Pubmed Central) - Feb 9, 2025
Our findings confirm and extend previous studies reporting the association of gliptins and antipsychotics on BP in other European populations. The association found for statins is new, thus more studies are needed to corroborate its validity.
- || linagliptin / Generic mfg.
Clinical, Retrospective data, Review, Journal: The effectiveness and safety of linagliptin within elderly type 2 diabetes mellitus: a meta-analysis and systematic review. (Pubmed Central) - Feb 4, 2025
The association found for statins is new, thus more studies are needed to corroborate its validity. Linagliptin is an effective drug with excellent safety for elderly T2DM.
- | Journal: Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians. (Pubmed Central) - Jan 12, 2025
The case illustrates that bariatric surgery is an effective and safe operation for people living with HIV. Due to complex needs and the need for regular follow-up; primary care, family, and HIV physicians can all collaborate in the care of individuals living with HIV and who underwent bariatric surgery.
- ||| Journal, Adverse events: Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses. (Pubmed Central) - Jan 12, 2025
These findings emphasize the need for careful patient monitoring, particularly in vulnerable populations, when prescribing these combinations. Further prospective studies are warranted to validate these findings and establish definitive causal relationships.
- | dexamethasone / Generic mfg., linagliptin / Generic mfg.
Journal: Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis. (Pubmed Central) - Jan 9, 2025
Further prospective studies are warranted to validate these findings and establish definitive causal relationships. Linagliptin treatment can attenuate the inflammatory response, protect against severe sepsis-induced vascular hyperpermeability, reduce multiorgan injury, and most importantly, improve the survival.
- | linagliptin / Generic mfg.
Preclinical, Journal: Chemical characterization and DPP IV inhibitory capacity of purified adzuki bean ?-vignin digest in comparison to soybean ?-conglycinin and in vitro effect of ?-vignin on diabetic-related outcomes. (Pubmed Central) - Jan 8, 2025
Molecular docking demonstrated peptides could bind to DPP IV at the same binding site as a diabetic medication, linagliptin. Digested AB ?-vignin significantly increased (p
- | linagliptin / Generic mfg.
Preclinical, Journal: Design and synthesis of novel 3,7-dihydro-1H-purine-2,6-diones as DPP-4 inhibitors: An in silico, in vitro and in vivo approach. (Pubmed Central) - Jan 3, 2025
The expressions of DPP-4 were observed by IHC, Flowcytometry, and RT-qPCR. The docked complexes of both compounds, along with the standard drug linagliptin, were subjected to molecular dynamics simulation for 140ns to evaluate the complexes' stability and binding affinity.
- | linagliptin / Generic mfg.
Journal: Water in nigella oil microemulsion for enhanced oral bioavailability of linagliptin. (Pubmed Central) - Jan 3, 2025
Nigella oil/IPM-based microemulsion was ranked as the most effective. The investigation highlighted the feasibility of w/o microemulsion for enhanced oral bioavailability of hydrophilic drugs like linagliptin.
- ||| Enrollment change: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Dec 26, 2024
P1/2, N=314, Active, not recruiting, Sponsor: Hoffmann-La Roche
The investigation highlighted the feasibility of w/o microemulsion for enhanced oral bioavailability of hydrophilic drugs like linagliptin. N=675 --> 314
- | linagliptin / Generic mfg.
Journal: Crosstalk between SIRT1/Nrf2 signaling and NLRP3 inflammasome/pyroptosis as a mechanistic approach for the neuroprotective effect of linagliptin in Parkinson's disease. (Pubmed Central) - Dec 21, 2024
(IL-1?) cascade with subsequent reduction in gasdermin D (GSDMD) expression. Therefore, the present study reveals the ability of linagliptin, through the activation of SIRT1/Nrf2 signaling, to suppress NLRP3 inflammasome-mediated pyroptosis and protect against rotenone-induced parkinsonism.
- | linagliptin / Generic mfg.
Journal: In-hospital linagliptin for management simplification and hypoglycemia reduction in very old patients with type 2 diabetes. (Pubmed Central) - Dec 12, 2024
Basal-bolus insulin use and clinical factors were associated with hypoglycemia. The linagliptin regimen could be considered as standard of care for older adult type 2 diabetes patients in the hospital setting.
- | linagliptin / Generic mfg.
Journal: Elucidating the linagliptin and fibroblast activation protein binding mechanism through molecular dynamics and binding free energy analysis. (Pubmed Central) - Dec 11, 2024
The R1 and R4 regions of linagliptin could be optimized to increase its FAP binding affinity. These findings can guide linagliptin structural optimization to improve its FAP binding affinity.
- | linagliptin / Generic mfg.
Journal: Treating hyperglycaemia in a patient with maternally inherited diabetes and deafness with an inhibitor of dipeptidyl peptidase-4: a case report and two-year follow-up. (Pubmed Central) - Dec 9, 2024
After two years of treatment with linagliptin, both glycated hemoglobin and pancreatic function have shown improvement to some extent. Although MIDD is a rare form of diabetes, due to distinctive management and associated comorbidities it is important to diagnose.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Fruzaqla (fruquintinib) / Takeda
Journal: Renal microangiopathy and immune complex glomerulonephritis induced by anti-tumour agents: A case report. (Pubmed Central) - Nov 26, 2024
The condition was controlled by stopping the anti-tumour drug, lowering glucose with linagliptin, and providing renal protection with Nephritis Rehabilitation Tablets, and the patient recovered well at the follow-up visit after 6 months. This case may be GMA induced by tislelizumab or fruquintinib and was examined in this study.
- | Trulicity (dulaglutide) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
Journal: Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function. (Pubmed Central) - Nov 17, 2024
The therapeutic effects after switching to tirzepatide included decrease in HbA1c, increase in eGFR, and decrease in BUN, when compared to when dulaglutide was used. A change from dulaglutide to tirzepatide, could inhibit renal impairment progression and improve renal function.
- | linagliptin / Generic mfg.
Journal: Impact of DPP-4 inhibitors on interleukin levels in type 2 diabetes mellitus. (Pubmed Central) - Nov 15, 2024
and IL-18 needed to be explored with more studies. Further trials should be performed to elucidate this anti-inflammatory effect of DPP-4i during treatment of T2DM.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P4 trial, Head-to-Head: The efiicacy and safety of biweekly cofrogliptin versus daily linagliptin as add-on in Patients with Type 2 Diabetes Inadequately Controlled by Dual Therapy(metformin and dapagliflozin): A Multicenter, Randomized, Open-Label, Active-Controlled,non-inferiority trial (EUDRACT) - Nov 10, 2024
P4, N=170, Not yet recruiting, Sponsor: Tongji Hosptial Affiliated to Tongji Medical College of Huazhong University fo Science and Technology; Tongji Hosptial Affiliated to Tongji Medical Co
- Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Patterns of Use of Noninsulin Antidiabetic Drugs in Colombia () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2282;
This group of patients with T2DM has been treated mainly with metformin (alone or in combination), DDP-4i and SGLT-2i. Most patients also used drugs for cardiovascular conditions, highlighting the importance of assessing cardiovascular risk and selecting T2DM drugs accordingly.
- | Nesina (alogliptin) / Takeda, Januvia (sitagliptin) / Merck (MSD)
Journal: Triazole scaffold-based DPP-IV Inhibitors for the management of Type-II Diabetes Mellitus: Insight into Molecular Docking and SAR. (Pubmed Central) - Nov 1, 2024
Clinical trials have demonstrated their efficacy as monotherapy or in combination with other antidiabetic agents. This review highlights the molecular docking studies and structure-activity relationship of potential synthetic derivatives that may act as lead molecules for future drug discovery and yield drug molecules with enhanced efficacy, potency and reduced toxicity profile.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Observational data, Journal: Noninsulin antidiabetic prescription patterns in Colombia: a cross-sectional study. (Pubmed Central) - Nov 1, 2024
This group of patients with T2DM has been treated mainly with metformin alone or in combination with other antidiabetic drugs, but despite the changes in treatment in recent years, a significant number of patients with concomitant cardiovascular conditions are not receiving appropriate antidiabetic agents. Sodium-glucose type 2 cotransporter or glucagon-like peptide-1 receptor agonists may offer additional benefits with reduced cardiovascular risk.
- | Trial primary completion date: ON TARGET DM: Comparison of Type 2 Diabetes Pharmacotherapy Regimens (clinicaltrials.gov) - Oct 28, 2024
P=N/A, N=270000, Recruiting, Sponsor: Kaiser Permanente
Sodium-glucose type 2 cotransporter or glucagon-like peptide-1 receptor agonists may offer additional benefits with reduced cardiovascular risk. Trial primary completion date: Jun 2024 --> Dec 2024
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Elucidation of DPP-4 involvement in systemic distribution and renal reabsorption of linagliptin by PBPK modeling with a cluster Gauss-Newton method. (Pubmed Central) - Oct 22, 2024
Trial primary completion date: Jun 2024 --> Dec 2024 Compared with previous PBPK analyses, the CGNM allowed us to incorporate greater model complexity (e.g., consideration of tDPP-4 expressions and in
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Sustained linagliptin administration: superior glycemic control and less pancreatic injury in diabetic rats. (Pubmed Central) - Oct 16, 2024
More reduction in collagen deposition and caspase-3 immunoreactivity in pancreatic tissue were observed in sustained linagliptin compared with oral linagliptin. In conclusion, sustained linagliptin administration provided superior glycemic control, which seems to be mediated by more reduction in pancreatic injury.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Extended duration linagliptin nanoparticles: a novel, safe and effective future of diabetes treatment? (Pubmed Central) - Oct 16, 2024
In conclusion, sustained linagliptin administration provided superior glycemic control, which seems to be mediated by more reduction in pancreatic injury. No abstract available
- ||| Victoza (liraglutide) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal, Adverse events: Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system. (Pubmed Central) - Oct 15, 2024
Subgroup analyses revealed varying correlations among specific drugs, potentially dose-dependent. Further large-scale studies are needed to evaluate class effect differences and elucidate mechanisms for guiding clinical use.
- ||| AJU-A51 / AJU Pharm
Clinical, P3 data, Journal: Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study. (Pubmed Central) - Oct 8, 2024
P3
Further large-scale studies are needed to evaluate class effect differences and elucidate mechanisms for guiding clinical use. Dapagliflozin and linagliptin FDC (AJU-A51) showed potent glucose-lowering effects, with good tolerability, in patients with T2D who had poor glycaemic control on metformin and linagliptin (ClinicalTrials.gov [NCT06329674]).
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Linagliptin's impact on lymphatic barrier and lymphangiogenesis in oral cancer with high glucose. (Pubmed Central) - Oct 7, 2024
Dapagliflozin and linagliptin FDC (AJU-A51) showed potent glucose-lowering effects, with good tolerability, in patients with T2D who had poor glycaemic control on metformin and linagliptin (ClinicalTrials.gov [NCT06329674]). By ameliorating the high glucose-induced disruption of the lymphatic endothelial barrier, linagliptin may reduce lymphangiogenesis and exhibit an inhibitory effect on lymphatic metastasis in oral cancer patients with diabetes.
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Dipeptidyl Peptidase 4 Inhibitor Linagliptin Improves Cardiac Function, Fibrosis and Apoptosis in a Swine Model of Chronic Myocardial Ischemia (S401A-C) - Oct 7, 2024 - Abstract #AHA2024AHA_3957;
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Antiproliferative Impact of Linagliptin on the Cervical Cancer Cell Line. (Pubmed Central) - Sep 29, 2024
The study has found that linagliptin successfully reduces the growth of cervical cancer cells with a time-dependent cytotoxic pattern. The potential anticancer mechanism of linagliptin can be inferred by analyzing the docking score and docking pattern between linagliptin and Hsp90, suggesting that linagliptin targets human Hsp 90.
- || Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Sep 26, 2024
P1/2, N=410, Active, not recruiting, Sponsor: Hoffmann-La Roche
The potential anticancer mechanism of linagliptin can be inferred by analyzing the docking score and docking pattern between linagliptin and Hsp90, suggesting that linagliptin targets human Hsp 90. Trial primary completion date: Aug 2024 --> Apr 2025
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Review, Journal: Maturity-onset diabetes of the young type 3 complicated with type 5: A case report and literature review. (Pubmed Central) - Sep 23, 2024
Treatment included insulin and linagliptin, with monitoring of blood glucose changes...In adolescents with diabetes who have congenital pancreatic and renal developmental defects, elevated high-density lipoprotein cholesterol, no spontaneous ketosis, insulin secretion defects, negative pancreatic autoantibodies, no significant insulin resistance, and who are not obese, gene testing should be conducted to screen for MODY. Accurate diagnosis and personalized treatment can aid in achieving glycemic control, improving quality of life, and optimizing reproductive planning.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Near-Infrared Stimuli-Responsive Hydrogel Promotes Cell Migration for Accelerated Diabetic Wound Healing. (Pubmed Central) - Sep 13, 2024
Linagliptin (LIN) was loaded into the composite hydrogel, and the drug release rate could be controlled by NIR laser irradiation...In the full-thickness skin defect model, the LIN-loaded composite hydrogel with NIR laser irradiation had the highest wound closure rate as compared with the pure hydrogel and LIN-loaded hydrogel groups. Therefore, this composite hydrogel can serve as an excellent platform for promoting wound healing and will find more practical value in clinical treatment.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Concomitant Use of Oral Anticoagulants with Oral Dipeptidyl Peptidase-4 Inhibitors and Serious Bleeding Events. (Pubmed Central) - Sep 12, 2024
The adjusted RORs ranged from 0.01 (0.00-0.20) for rivaroxaban/lisinopril + saxagliptin to 2.99 (0.74-12.11) for apixaban/lisinopril + linagliptin. While we could not confirm previously identified signals because of statistical imprecision, several numerically elevated estimates still warrant caution in concomitant use and further examination.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Linagliptin mitigates cisplatin-induced kidney impairment via mitophagy regulation in rats, with emphasis on SIRT-3/PGC-1?, PINK-1 and Parkin-2. (Pubmed Central) - Sep 10, 2024
These findings suggest a potential role for linagliptin in improving cancer treatment outcomes. Clinical trials are warranted to further investigate and validate its efficacy in a clinical setting.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Retrospective data, Journal: Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid. (Pubmed Central) - Sep 5, 2024
Clinical trials are warranted to further investigate and validate its efficacy in a clinical setting. No abstract available
- | metformin / Generic mfg.
New trial, HEOR, Combination therapy, Cost effectiveness: Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study. (clinicaltrials.gov) - Aug 25, 2024
P=N/A, N=200, Recruiting, Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Retrospective data, Journal: Association between dipeptidyl peptidase-4 inhibitor use and risk of Parkinson's disease among patients with diabetes mellitus: a retrospective cohort study. (Pubmed Central) - Aug 23, 2024
DPP-4 inhibitors were discovered in this study to not be associated with increased PD risk. This result was confirmed when the analysis was conducted individually for the 4 investigated DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and vildagliptin).
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Reactive Eccrine Syringofibroadenoma: A Case Report of a Rare Disease (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4433;
Multiple anastomosing cords of benign epithelial cells surrounded by a loose fibrovascular stroma can be seen in the histopathological analysis of lesions. ESFA stains positively with epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) .
- Dupixent (dupilumab) / Sanofi, Regeneron
Bullous pemphigoid secondary to dipepitidyl peptidase-4 inhibitors complicated by reactive perforating dermatosis with response to dupilumab (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2630;
Case report: We present the case of an 81-year-old woman with a history of type II DM treated with linagliptin...With all this, the diagnosis of DPP4i-induced BP with a partial response to topical clobetasol propionate was established... In conclusion, we present the case of a woman with DPP4i-induced BP with secondary RPD with a good response to dupilumab.
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Pemphigoid nodularis induced by gliptins (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2543;
More than 50 cases of pemphigoid nodularis have been reported so far, but only in few of them a particular trigger could be identified in contrast to BP in general which can be precipitated by various physical or chemical agents, and medications, DPP-4i among them. A few cases of pemphigoid nodularis under gliptins were found in the literature, which may support linagliptin as a possible
- Dupixent (dupilumab) / Sanofi, Regeneron
A case of immunoglobulin G4-related disease that pruritic skin lesions preceded 9 years to the diagnosis and that lymphadenopathy became apparent leading to the diagnosis while receiving dupilumab (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2499;
IgG4-RD should be considered as one of them. In addition, the majority of the reported cases of IgG4-RD administered DUP showed favorable outcomes, but our case showed opposite response.
- Opdivo (nivolumab) / BMS
Nivolumab associated DRESS syndrome: A case report. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1925;
He was diagnosed as a case carcinoma of lungs with metastasis to vertebra (L3,L5,S1) while investigating for chronic paresthesia of upper and lower limb two and half months back and had received multiple medicines namely intravenous immunoglobulins , paracetamol, gabapentin, pregabalin and duloxetine, linagliptin- Metformin, a blend of PEA, genistein and daidzein, melatonin tablets, pramipexole and Zolpidem tartrate for a period of two weeks. Not applicable
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
A RARE CAUSE OF SUSTAINED ABNORMALLY ELEVATED LIVER ENZYMES: MATURITY-ONSET DIABETES OF THE YOUNG TYPE 5 ASSOCIATED CHOLESTASIS (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_957;
(HNF1?) gene, which is a transcription factor expressed in various organs. Involved in the regulation of the expression of liver enzymes, when mutated may result in biochemical abnormalities.
- | Marizev (omarigliptin) / Merck (MSD)
Trial initiation date, HEOR, Real-world evidence: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (clinicaltrials.gov) - Jul 17, 2024
P4, N=938, Not yet recruiting, Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Involved in the regulation of the expression of liver enzymes, when mutated may result in biochemical abnormalities. Initiation date: Jun 2024 --> Sep 2024
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Trulicity (dulaglutide) / Eli Lilly
Preclinical, Journal: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD). (Pubmed Central) - Jun 26, 2024
The two pharmacological combinations showed beneficial effects in treating obesity and MASLD. However, the combination of SGLT2i and GLP1RA showed more potent beneficial effects on MASLD than SGLT2i and DPP4i and, therefore, should be the recommended combination.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal: Computational Screening for the Dipeptidyl Peptidase-IV Inhibitory Peptides from Putative Hemp Seed Hydrolyzed Peptidome as a Potential Antidiabetic Agent. (Pubmed Central) - Jun 19, 2024
Based on the predictive outcomes, FNVDTE from edestin and EAQPST from vicilin emerged as promising candidates for DPPIV inhibitors. We anticipate that our findings may pave the way for the development of alternative DPPIV inhibitors.